Home > Oncology > ASCO 2022 > DESTINY-Breast04: Practice-changing results of T-DXd in HER2-low breast cancer

DESTINY-Breast04: Practice-changing results of T-DXd in HER2-low breast cancer

Presented By
Dr Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ASCO 2022
Trial
Phase 3, DESTINY-Breast04
Trastuzumab deruxtecan (T-DXd) outperformed therapy by physician’s choice in patients with HER2-low unresectable or metastatic breast cancer who had received 1 or 2 previous lines of chemotherapy. T-DXd is the first HER2-targeted therapy to outperform the standard-of-care in terms of progression-free survival and overall survival in the hard-to-treat HER2-low breast cancer population. The HER2-status of patients with breast cancer is defined by immunohistochemistry (IHC) scores. HER2-low is defined as an IHC score of 1+ or 2+ with in situ hybridization (ISH)- status. The options for these patients, especially in later lines of therapy, are limited. The phase 3 DESTINY-Breast04 trial (NCT03734029) randomised patients with HER2-low unresectable or metastatic breast cancer, who had received 1 or 2 prior lines or chemotherapy and were refractory to endocrine th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on